Alpha Teknova (TKNO) Stock Overview
Produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
TKNO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Alpha Teknova, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.11 |
| 52 Week High | US$10.37 |
| 52 Week Low | US$3.85 |
| Beta | 0.41 |
| 1 Month Change | -11.23% |
| 3 Month Change | -29.02% |
| 1 Year Change | -52.21% |
| 3 Year Change | -20.50% |
| 5 Year Change | n/a |
| Change since IPO | -83.56% |
Recent News & Updates
Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.00
Nov 12
Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce
Sep 25Recent updates
Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.00
Nov 12Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce
Sep 25Alpha Teknova, Inc.'s (NASDAQ:TKNO) 26% Cheaper Price Remains In Tune With Revenues
Jul 22Shareholders Will Probably Not Have Any Issues With Alpha Teknova, Inc.'s (NASDAQ:TKNO) CEO Compensation
Jun 11
Acquisitions And Collaborations Will Expand Cell And Gene Therapy Portfolio
Expansion through collaborations and acquisitions aims to boost top-line growth, margins, and financial stability amidst anticipated market rebound.Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 06Alpha Teknova, Inc. (NASDAQ:TKNO) Stocks Pounded By 31% But Not Lagging Industry On Growth Or Pricing
Feb 28Calculating The Fair Value Of Alpha Teknova, Inc. (NASDAQ:TKNO)
Feb 23Revenues Tell The Story For Alpha Teknova, Inc. (NASDAQ:TKNO) As Its Stock Soars 28%
Dec 14Revenues Tell The Story For Alpha Teknova, Inc. (NASDAQ:TKNO) As Its Stock Soars 42%
Oct 15Alpha Teknova, Inc. (NASDAQ:TKNO) Might Not Be As Mispriced As It Looks After Plunging 30%
Jun 27Not Many Are Piling Into Alpha Teknova, Inc. (NASDAQ:TKNO) Stock Yet As It Plummets 25%
Apr 24Health Check: How Prudently Does Alpha Teknova (NASDAQ:TKNO) Use Debt?
Jan 22Some Analysts Just Cut Their Alpha Teknova, Inc. (NASDAQ:TKNO) Estimates
Aug 14Take Care Before Jumping Onto Alpha Teknova, Inc. (NASDAQ:TKNO) Even Though It's 30% Cheaper
Apr 17Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported, And Analysts Assigned A US$23.00 Price Target
May 14Shareholder Returns
| TKNO | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -12.6% | 3.0% | 3.1% |
| 1Y | -52.2% | 3.0% | 14.6% |
Return vs Industry: TKNO underperformed the US Life Sciences industry which returned 3% over the past year.
Return vs Market: TKNO underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| TKNO volatility | |
|---|---|
| TKNO Average Weekly Movement | 9.6% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TKNO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TKNO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 173 | Stephen Gunstream | www.teknova.com |
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
Alpha Teknova, Inc. Fundamentals Summary
| TKNO fundamental statistics | |
|---|---|
| Market cap | US$220.00m |
| Earnings (TTM) | -US$18.22m |
| Revenue (TTM) | US$39.80m |
Is TKNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TKNO income statement (TTM) | |
|---|---|
| Revenue | US$39.80m |
| Cost of Revenue | US$27.48m |
| Gross Profit | US$12.33m |
| Other Expenses | US$30.55m |
| Earnings | -US$18.22m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 30.97% |
| Net Profit Margin | -45.78% |
| Debt/Equity Ratio | 18.0% |
How did TKNO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 17:51 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alpha Teknova, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Knight | KeyBanc Capital Markets Inc. |